Removing industrial trans fat from foods

BMJ (Online)

Volumn 340, Issue 7756, 2010, Pages 1094-

  Mozaffarian, Dariush ^a   Stampfer, Meir J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROGENATED VEGETABLE OIL; LINOLEIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LP(A) LIPOPROTEIN; OMEGA 3 FATTY ACID; TRANS FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CALORIC INTAKE; CARDIOVASCULAR RISK; CATERING SERVICE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSUMER; CORONARY ARTERY DISEASE; DENMARK; DIABETES MELLITUS; EDITORIAL; ENDOTHELIAL DYSFUNCTION; FAT INTAKE; FOOD; FOOD PACKAGING; FOOD SAFETY; HEALTH CARE POLICY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LAW; PRIORITY JOURNAL; PUBLIC HEALTH; SHELF LIFE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; UNITED STATES;

DIETARY FATS; FOOD INDUSTRY; GREAT BRITAIN; HUMANS; LEGISLATION, FOOD; TRANS FATTY ACIDS;

EID: 77953943136     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1826     Document Type: Editorial

References (12)

1. UK Faculty of Public Health/Royal Society for Public Health. 12 steps to better public health: a manifesto. www.fphm.org.uk/resources/AtoZ/manifesto/ manifesto.pdf.
2. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:1601-13.[Free Full Text]
3. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 2009;5:335-44.[CrossRef][Web of Science][Medline]
4. Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 2009;63(suppl 2):S22-33.[CrossRef][Medline]
5. Craig-Schmidt MC. Worldwide consumption of trans-fatty acids. In: Sebedio JL, Christie WW, eds. Trans fatty acids in human nutrition. Oily Press, 1998:50-113.
6. Mozaffarian D, Abdollahi M, Campos H, Houshiarrad A, Willett WC. Consumption of trans fats and estimated effects on coronary heart disease in Iran. Eur J Clin Nutr 2007;61:1004-10.[CrossRef][Web of Science][Medline]
7. Asgary S, Nazari B, Sarrafzadegan N, Parkhideh S, Saberi S, Esmaillzadeh A, et al. Evaluation of fatty acid content of some Iranian fast foods with emphasis on trans fatty acids. Asia Pac J Clin Nutr 2009;18:187-92.[Web of Science][Medline]
8. Ratnayake WM, L'Abbe MR, Mozaffarian D. Nationwide product reformulations to reduce trans fatty acids in Canada: when trans fat goes out, what goes in? Eur J Clin Nutr 2009;63:808-11. [CrossRef][Web of Science][Medline]
9. Angell SY, Silver LD, Goldstein GP, Johnson CM, Deitcher DR, Frieden TR, et al. Cholesterol control beyond the clinic: New York City's trans fat restriction. Ann Intern Med 2009;151:129-34. [Abstract/Free Full Text]
10. Leth T, Jensen HG, Mikkelsen AA, Bysted A. The effect of the regulation on trans fatty acid content in Danish food. Atheroscler Suppl 2006;7:53-6.[Web of Science][Medline]
11. Nielsen K. Is the quality and cost of food affected if industrially produced trans fatty acids are removed? Atheroscler Suppl 2006;7:61-2.[Web of Science][Medline]
12. Department of Health. National service framework for coronary heart disease. 2010. www.dh.gov.uk/en/Healthcare/Longtermconditions/Vascular/ Coronaryheartdisease/Nationalserviceframework/DH-096623.